Preoperative Management of Blood Thinning Agents During Cutaneous Surgery

Gajebasia, Sareena; Kerr, Ron; Affleck, Andrew

Published in: Journal of the American Academy of Dermatology

DOI: 10.1016/j.jaad.2020.08.075

Publication date: 2021

Licence: CC BY-NC-ND

Document Version: Peer reviewed version

Citation for published version (APA):
Preoperative Management of Blood Thinning Agents During Cutaneous Surgery: the need for an individualised approach

Dr Sareena Gajebasia, Dermatology Registrar, BMBS, iBSc(Hons), Dr Ron Kerr, Consultant Haematologist, MBChB, MRCP, FRCPath, MD, Dr Andrew Affleck, MBChB, MRCP

PII: S0190-9622(20)32470-1
DOI: https://doi.org/10.1016/j.jaad.2020.08.075
Reference: YMJD 15138

To appear in: Journal of the American Academy of Dermatology

Received Date: 3 July 2020
Revised Date: 11 August 2020
Accepted Date: 12 August 2020


This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2020 Published by Elsevier on behalf of the American Academy of Dermatology, Inc.
This manuscript version is made available under the CC-BY-NC-ND 4.0 license
http://creativecommons.org/licenses/by-nc-nd/4.0/
Article type: Notes and Comments

Title: Preoperative Management of Blood Thinning Agents During Cutaneous Surgery: the need for an individualised approach

Dr Sareena Gajebasia
Dermatology Registrar
BMBS, iBSc(Hons)
Department of Dermatology, Ninewells Hospital, Dundee, UK

Dr Ron Kerr
Consultant Haematologist
MBChB, MRCP, FRCPath, MD
Department of Haematology, Ninewells Hospital, Dundee, UK

Dr Andrew Affleck
MBChB, MRCP
Consultant Dermatologist and Mohs Surgeon
Department of Dermatology, Ninewells Hospital, Dundee, UK

Word count: 499
References: 5

Funding: none.

Conflicts of interest: none.

Correspondence:

Dr Sareena Gajebasia
Department of Dermatology
Level 8, Ninewells Hospital, James Arrott Drive, Dundee, DD1 9SY
sareena.gajebasia@nhs.net

Twitter handle: Dr Andy Affleck @SherlockianDerm

Key words: dermatologic surgery, blood thinning medications, anticoagulant, antiplatelet, bleeding, risk, stroke
Taylor et al.\textsuperscript{1} concluded that in Mohs Micrographic Surgery the risk of bleeding is very low and advocate staying on blood-thinning medications.\textsuperscript{1} This is encouraging, however, complications arising from the documented bleeding events including skin graft failure and secondary infection, were not stated. This is important to know for the procedure outcome.

We propose a patient-centred approach when considering continuing or withholding blood-thinning medications during cutaneous surgery, taking into account the risk:benefit ratio of the medication and surgery. A fictional case will demonstrate this:

A 66-year-old diabetic female with atrial fibrillation, on a direct oral anticoagulant (DOAC) for stroke prevention, is due to have a 4cm squamous cell carcinoma on her scalp excised to the periosteum with a split-thickness skin graft repair.

The bleeding risk should be balanced against the risk of withholding the DOAC. CHA(2)DS(2)-VASc score predicts the risk of stroke,\textsuperscript{2} and this patient scores 3 (sex, age and diabetes mellitus) which equates to a risk of 37 per 1000 people in one year having a stroke if not anticoagulated.\textsuperscript{3} Therefore, this patient’s risk of stroke on one day if not anticoagulated is estimated as 1 in 9865 ((37/1000)/365); although surgery-associated stress may increase this risk. The bleeding risk should be reviewed by assessing patient risk factors and their anticoagulant medication. A dermatologist cannot assume what is an acceptable risk to a patient nor presume to tell a patient to stop medications without a risk:benefit discussion; quantifying the risks may help. In the UK the Montgomery judgement conveys this concept and is a legal principle in informed consent.\textsuperscript{4} It ruled that doctors have “a duty to take reasonable care to ensure that the patient is aware of any material risks involved”.\textsuperscript{4}

Careful consideration of blood-thinners should be given in other complex reconstructions eg. paramedian flap repair, local skin flaps, hard to compress sites eg. periocular, where excessive bleeding can be problematic. The anticoagulant should be considered. Warfarin
requires a longer cessation period (5-10 days) compared to DOACs (24-48 hours) to normalise coagulation and once restarted takes longer to achieve therapeutic anticoagulation, therefore it has an increased risk of thromboembolism on cessation compared to DOACs.

Nuanced strategies may be considered; egs. swapping clopidogrel for aspirin as it is associated with less bleeding, performing surgery at the DOAC trough level, stopping one of two blood-thinning medications or adjusting the medication so that it has reduced but not zero efficacy. The patient’s cardiologist or primary care physician should be consulted if modification is required.

The American College of Cardiology recommends performing procedures with uninterrupted anticoagulation when there is ‘no clinically important bleeding risk’ which we suggest would be most dermatologic surgery. It may never be appropriate to stop blood-thinning medications in patients with coronary drug-eluting stents or valvular heart disease. However, there is a case for withholding/adjusting these medications when the risk:benefit ratio is favourable eg. individuals with a low risk of a vascular event undergoing complex skin surgery. We emphasise undertaking individual patient assessments and involving patients in the decision.

References


2. Lip GYH, Nieuwlaat R, Pisters R, Lane DA, Crijns HJGM. Refining Clinical Risk Stratification for Predicting Stroke and Thromboembolism in Atrial Fibrillation Using
a Novel Risk Factor-Based Approach: The Euro Heart Survey on Atrial Fibrillation.


Taylor et al.\textsuperscript{1} concluded that in Mohs Micrographic Surgery the risk of bleeding is very low and advocate staying on blood-thinning medications.\textsuperscript{1} This is encouraging, however, complications arising from the documented bleeding events including skin graft failure and secondary infection, were not stated. This is important to know for the procedure outcome.

We propose a patient-centred approach when considering continuing or withholding blood-thinning medications during cutaneous surgery, taking into account the risk:benefit ratio of the medication and surgery. A fictional case will demonstrate this;

A 66-year-old diabetic female with atrial fibrillation, on a direct oral anticoagulant (DOAC) for stroke prevention, is due to have a 4cm squamous cell carcinoma on her scalp excised to the periosteum with a split-thickness skin graft repair.

The bleeding risk should be balanced against the risk of withholding the DOAC. CHA(2)DS(2)-VASc score predicts the risk of stroke,\textsuperscript{2} and this patient scores 3 (sex, age and diabetes mellitus) which equates to a risk of 37 per 1000 people in one year having a stroke if not anticoagulated.\textsuperscript{3} Therefore, this patient’s risk of stroke on one day if not anticoagulated is estimated as 1 in 9865 ((37/1000)/365); although surgery-associated stress may increase this risk. The bleeding risk should be reviewed by assessing patient risk factors and their anticoagulant medication. A dermatologist cannot assume what is an acceptable risk to a patient nor presume to tell a patient to stop medications without a risk:benefit discussion; quantifying the risks may help. In the UK the Montgomery judgement conveys this concept and is a legal principle in informed consent.\textsuperscript{4} It ruled that doctors have “a duty to take reasonable care to ensure that the patient is aware of any material risks involved”.\textsuperscript{4}

Careful consideration of blood-thinners should be given in other complex reconstructions eg. paramedian flap repair, local skin flaps, hard to compress sites eg. periocular, where
excessive bleeding can be problematic. The anticoagulant should be considered. Warfarin requires a longer cessation period (5-10 days) compared to DOACs (24-48 hours) to normalise coagulation and once restarted takes longer to achieve therapeutic anticoagulation, therefore it has an increased risk of thromboembolism on cessation compared to DOACs. Nuanced strategies may be considered; e.g.s swapping clopidogrel for aspirin as it is associated with less bleeding, performing surgery at the DOAC trough level, stopping one of two blood-thinning medications or adjusting the medication so that it has reduced but not zero efficacy. The patient’s cardiologist or primary care physician should be consulted if modification is required.

The American College of Cardiology recommends performing procedures with uninterrupted anticoagulation when there is ‘no clinically important bleeding risk’⁵ which we suggest would be most dermatologic surgery. It may never be appropriate to stop blood-thinning medications in patients with coronary drug-eluting stents or valvular heart disease. However, there is a case for withholding/adjusting these medications when the risk:benefit ratio is favourable e.g. individuals with a low risk of a vascular event undergoing complex skin surgery. We emphasise undertaking individual patient assessments and involving patients in the decision.

References


2. Lip GYH, Nieuwlaat R, Pisters R, Lane DA, Crijns HJGM. Refining Clinical Risk Stratification for Predicting Stroke and Thromboembolism in Atrial Fibrillation Using
a Novel Risk Factor-Based Approach: The Euro Heart Survey on Atrial Fibrillation.

*Chest* 2010;137(2):263-272.


